Search filters

List of works by Timothy Hughes

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.

scientific article

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

scientific article

A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response.

scientific article published on 5 March 2009

Apoptosis regulatory gene NEDD2 maps to human chromosome segment 7q34-35, a region frequently affected in haematological neoplasms

scientific article

BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance

scientific article published on 25 June 2013

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

scientific article

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors

scientific article published on 4 February 2010

Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity

scientific article published on 11 February 2010

Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia

scientific article published on 06 June 2020

Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells

scientific article published on 24 April 2012

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

scientific article

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

scientific article

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.

scientific article published on 30 July 2009

Detection of minimal residual disease in an AML patient with trisomy 8 using interphase FISH

scientific article published on 01 August 1997

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

scientific article

Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients

scientific article published on 06 November 2013

Erratum: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

scholarly article published in Leukemia

Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

scholarly article published in Leukemia

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

scientific article published on 03 March 2020

False-positive results with PCR to detect leukaemia-specific transcript.

scientific article published in April 1990

High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse

scientific article published on 30 July 2020

Imatinib mesylate causes growth plate closure in vivo.

scientific article published on 23 July 2009

Improved results with PCR for chronic myeloid leukaemia

scientific article published on 01 September 1990

In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy

scientific article published on 02 January 2021

Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.

scientific article published on 09 October 2013

Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia

scientific article published in December 2004

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

scientific article

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

scientific article published on 27 March 2019

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

scientific article published on 3 February 2016

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

scientific article published on 07 January 2021

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st

scientific article

Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation

scientific article published on 15 February 2013

Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials

scientific article published on 21 December 2015

Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination

scientific article

Matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia in chronic phase: comparison of ex vivo and in vivo T-cell depletion.

scientific article published in January 1993

Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics

scientific article published on 01 December 1999

Mutational analysis in chronic myeloid leukemia: when and what to do? ⬇️

scientific article published on March 1, 2011

NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis

scientific article published on 13 July 2012

Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells

scientific article published on 11 February 2010

Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.

scientific article published on 12 July 2017

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

scientific article

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

scientific article

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

scientific article

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

scientific article published on 10 December 2009

OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.

scientific article published on 2 September 2010

OCT-1 as a determinant of response to antileukemic treatment.

scientific article

OCT1 and imatinib transport in CML: is it clinically relevant?

scientific article published on 30 June 2015

Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia

scientific article published on 01 April 1997

Polymerase chain reaction for detection of residual leukaemia

scientific article published on 01 April 1989

Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells

scientific article published on 13 February 2015

Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.

scientific article

Practical Considerations for Monitoring Patients With Chronic Myeloid Leukemia ⬇️

scientific article published on October 1, 2010

Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.

scientific article

Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells.

scientific article

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia

scientific article published on 7 November 2016

Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment

scientific article published on 2 September 2014

Response to 'Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?'

scientific article

Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning

scientific article published on 01 January 1992

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells

scientific article published on 5 March 2009

Significance of residual leukaemia transcripts after bone marrow transplant for CML

scientific article published on 01 January 1990

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

scientific article published on 12 March 2009

Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow

scientific article published on 01 December 1989

Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells

scientific article published on 30 April 2020

Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors ⬇️

scientific article published on April 23, 2012

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

scientific article published on 3 August 2017

Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia

scientific article published on 12 May 2014

TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries

scientific article published on 30 March 2020

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

scientific article published on 22 February 2016

The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment

scientific article published on 15 July 2016

Therapeutic Targeting of BCR-ABL: Prognostic Markers of Response and Resistance Mechanism in Chronic Myeloid Leukaemia ⬇️

scientific article published on January 1, 2012

Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis.

scientific article

There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge

scientific article published on 10 November 2020

Paulina is supported by:

About Paulina

Help